Kalbe Farma Past Earnings Performance
Past criteria checks 2/6
Kalbe Farma has been growing earnings at an average annual rate of 4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.2% per year. Kalbe Farma's return on equity is 13%, and it has net margins of 9.6%.
Key information
4.0%
Earnings growth rate
4.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 8.2% |
| Return on equity | 13.0% |
| Net Margin | 9.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kalbe Farma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 32,126,890 | 3,080,202 | 7,869,444 | 368,379 |
| 30 Jun 24 | 31,598,456 | 3,042,847 | 7,607,184 | 331,580 |
| 31 Mar 24 | 30,943,002 | 2,868,591 | 7,612,377 | 327,984 |
| 31 Dec 23 | 30,449,134 | 2,766,748 | 7,591,031 | 322,297 |
| 30 Sep 23 | 30,312,738 | 2,961,621 | 7,491,226 | 322,526 |
| 30 Jun 23 | 30,237,846 | 3,274,258 | 7,310,087 | 338,900 |
| 31 Mar 23 | 29,786,958 | 3,403,045 | 7,186,180 | 296,529 |
| 31 Dec 22 | 28,933,503 | 3,382,210 | 7,008,307 | 286,805 |
| 30 Sep 22 | 28,344,270 | 3,381,401 | 6,989,942 | 297,645 |
| 30 Jun 22 | 27,765,354 | 3,323,285 | 7,023,885 | 283,039 |
| 31 Mar 22 | 27,261,485 | 3,302,038 | 6,930,882 | 283,381 |
| 31 Dec 21 | 26,261,195 | 3,183,621 | 6,800,994 | 285,159 |
| 30 Sep 21 | 25,115,512 | 2,993,591 | 6,448,388 | 285,589 |
| 30 Jun 21 | 23,878,570 | 2,843,018 | 6,243,097 | 294,376 |
| 31 Mar 21 | 23,332,456 | 2,780,456 | 6,182,445 | 287,580 |
| 31 Dec 20 | 23,112,655 | 2,733,260 | 6,238,255 | 281,059 |
| 30 Sep 20 | 22,902,507 | 2,618,701 | 6,421,524 | 303,010 |
| 30 Jun 20 | 23,059,326 | 2,636,125 | 6,466,046 | 292,713 |
| 31 Mar 20 | 23,063,580 | 2,580,962 | 6,547,833 | 292,968 |
| 31 Dec 19 | 22,633,476 | 2,506,765 | 6,486,989 | 286,655 |
| 30 Sep 19 | 22,222,813 | 2,568,165 | 6,314,947 | 253,841 |
| 30 Jun 19 | 21,872,440 | 2,499,430 | 6,342,472 | 249,703 |
| 31 Mar 19 | 21,424,910 | 2,462,761 | 6,292,038 | 245,288 |
| 31 Dec 18 | 21,074,306 | 2,457,129 | 6,243,727 | 237,873 |
| 30 Sep 18 | 20,770,524 | 2,428,630 | 6,364,869 | 242,177 |
| 30 Jun 18 | 20,496,345 | 2,403,213 | 6,297,021 | 248,906 |
| 31 Mar 18 | 20,298,678 | 2,404,792 | 6,240,601 | 238,989 |
| 31 Dec 17 | 20,182,120 | 2,403,606 | 6,211,514 | 235,818 |
| 30 Sep 17 | 20,087,979 | 2,376,474 | 6,309,736 | 225,629 |
| 30 Jun 17 | 19,884,741 | 2,369,779 | 6,270,603 | 208,446 |
| 31 Mar 17 | 19,722,837 | 2,324,750 | 6,271,926 | 201,003 |
| 31 Dec 16 | 19,374,231 | 2,299,735 | 6,113,081 | 191,713 |
| 30 Sep 16 | 19,135,808 | 2,207,683 | 5,992,389 | 184,289 |
| 30 Jun 16 | 18,723,481 | 2,087,332 | 5,877,673 | 174,407 |
| 31 Mar 16 | 18,190,514 | 2,038,815 | 5,708,469 | 167,739 |
| 31 Dec 15 | 17,887,464 | 2,004,237 | 5,664,066 | 163,365 |
| 30 Sep 15 | 17,737,870 | 2,078,487 | 5,684,861 | 158,315 |
| 30 Jun 15 | 17,708,558 | 2,136,225 | 5,643,279 | 155,102 |
| 31 Mar 15 | 17,548,723 | 2,101,577 | 5,531,142 | 147,835 |
| 31 Dec 14 | 17,368,533 | 2,066,022 | 5,423,677 | 143,024 |
| 30 Sep 14 | 17,320,906 | 2,040,142 | 5,264,833 | 139,464 |
| 30 Jun 14 | 16,960,755 | 1,990,437 | 5,144,638 | 139,559 |
| 31 Mar 14 | 16,578,629 | 1,968,549 | 5,058,364 | 143,531 |
| 31 Dec 13 | 16,002,131 | 1,919,508 | 4,880,697 | 135,388 |
Quality Earnings: LCLA has high quality earnings.
Growing Profit Margin: LCLA's current net profit margins (9.6%) are lower than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LCLA's earnings have grown by 4% per year over the past 5 years.
Accelerating Growth: LCLA's earnings growth over the past year (4%) is below its 5-year average (4% per year).
Earnings vs Industry: LCLA earnings growth over the past year (4%) did not outperform the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: LCLA's Return on Equity (13%) is considered low.